Xphozah (Tenapanor) is a sodium-hydrogen exchanger 3 (NHE3) inhibitor with tenapanor hydrochloride as the active ingredient. First approved in the United States in 2019, this medication is primarily used to reduce serum phosphorus levels in patients with chronic kidney disease (CKD) undergoing dialysis. It serves as an add-on treatment for patients who have an inadequate response to or intolerance of phosphate binders.

Purchase Channels for Xphozah (Tenapanor)

Overseas Purchase

Patients may consult and purchase Xphozah at hospital pharmacies or legitimate drugstores in countries or regions where the medication has been launched.

Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make budgets and plans in advance before purchasing.

Purchase through Medical Service Institutions

Patients can consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.

These institutions usually provide legal import channels and offer professional consultation and guidance.

Purchase and Usage Precautions for Xphozah (Tenapanor)

Strict Contraindicated Populations

Children under 6 years old: Due to the risk of diarrhea and severe dehydration.

Patients with known or suspected mechanical gastrointestinal obstruction.

Dosage Adjustment Principles

Initial dosage: 30mg twice daily.

Adjust dosage based on serum phosphorus levels and gastrointestinal tolerance.

Must be taken before breakfast and dinner.

Special Medication Timing

Dialysis patients should avoid taking the medication immediately before dialysis; it should be taken before the next meal after dialysis.

Handling of missed doses: Skip the missed dose and take the next dose at the regular time.

Diarrhea Risk

Diarrhea occurred in 43-53% of patients in clinical trials.

Severe diarrhea was reported in 5% of patients.

Dehydration and hyponatremia occurred in less than 1% of patients.

Methods to Distinguish Authenticity of Xphozah (Tenapanor)

Verification of Appearance and Specifications

10mg: Yellow, oval, biconvex, film-coated tablets; engraved with "" on one side and "T10" on the other.

20mg: Brown, oval, biconvex, film-coated tablets; engraved with "" on one side and "T20" on the other.

30mg: Red, oval, biconvex, film-coated tablets; engraved with "" on one side and "T30" on the other.

Confirmation of Packaging Integrity

Packaged in white opaque high-density polyethylene bottles.

Contains a silica gel canister (as a desiccant).

Equipped with a child-resistant polypropylene screw cap.

Verification of Storage Conditions

Temperature: 20°C to 25°C (68°F to 77°F).

Short-term fluctuations between 15°C and 30°C (59°F to 86°F) are permitted.

The bottle must be kept tightly closed to prevent moisture; store and dispense in the original bottle.